Cue Biopharma filed a Form 8-K reporting Q4 and FY 2025 results, including Q4 collaboration revenue of USD 21.94 million and net income of USD 1.59 million. Q4 research and development expense rose more than doubled to USD 16.53 million, driven by higher CUE-401 manufacturing and lab costs and one-time acquired in-process R&D tied to the ImmunoScape collaboration. FY 2025 collaboration revenue increased nearly tripled to USD 27.47 million, reflecting revenue recognized from the ImmunoScape collaboration and license agreement. FY 2025 net loss narrowed 35% to USD 26.6 million, and cash and cash equivalents were USD 27.14 million at year-end. The company said it advanced CUE-401 toward IND readiness and reported raising net proceeds of USD 10.2 million in an underwritten public offering, while CEO Usman Azam said the company is positioned to advance its Immuno-STAT platform and CUE-401 toward the clinic.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-108292), on March 16, 2026, and is solely responsible for the information contained therein.
Comments